+ Watch VSTM
on My Watchlist
MIT creme de la creme.
Short. No revenues… if gets some might change to neutral.
USB analyst Matthew Roden thinks the company has a formular likely to prove crucial in the fight against many types of cancer.
Verastem took a body blow with the news that salinomycin was no longer in line for clinical trials, and cushioned the blow with the announcement of a new partnership with Eisai. The company is still keeping a lid on much of what they're doing but I see a low market cap, a solid cash position, and an experienced management team. While my skepticism level remains high, I'll look for a leg back up from here.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions